Healthy male/female adults
Conditions
Interventions
None listed
Sponsors
CPCC Company Limited
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Healthy male/female subjects ranging in age from 20 to 59, at informed consent. (2) Subjects who can give informed consent to take part in this research, after being provided with an explanation of the protocol detail.
Exclusion criteria
Exclusion criteria: (1) Subjects being under some kind of continuous medical treatment, except applying a nasal spray and eye drops. (2) Subjects who took a steroid within the last three months from the time point of clinic visiting. (3) Subjects who apply a steroid all the year around, except a seasonal use and deteriorating conditions. (4) Subjects who were vaccinated against some kind of disease within the past two weeks to the clinic visiting. (5) Pregnant, possibly pregnant, and lactating women. (6) Subjects with previous and/or current medical history of serious diseases in heart, liver, kidney and/or digestive organs. (7) Subjects touching excessive alcohol. (8) Subjects with serious drug and/or food allergy. (9) Subjects who are under the other clinical tests with some kind of medicine/food, or participated in those within four weeks after this research, or are planning to join those after giving informed consent to participate in this research. (10) Subjects who donated their blood components and/or whole blood (200 mL) within a month to this research. (11) Males who donated their whole blood (400 mL) within the last three months to this research. (12) Females who donated their whole blood (400 mL) within the last four months to this research. (13) Males who will be collected in total of their blood (1200 mL) within the last twelve months, after adding the blood amounts planning to be sampled in this research. (14) Females who will be collected in total of their blood (800 mL) within the last twelve month s, after adding the blood amounts planning to be sampled in this research. (15) Others who have been determined as ineligible for participation, judging from the principal/sub investigator's opinions.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Counts of white blood cell, red blood cell, and platelet | — |
Secondary
| Measure | Time frame |
|---|---|
| Examinations of blood cell - - (1) expressing protein (conventional/ghost flow cytometry), (2) form (conventional/ghost flow cytometry, and microscopic observation), (3) proliferation (general cell counting, or conventional/ghost flow cytometry), (4) differentiation induction (conventional/ghost flow cytometry, microscopic observation, reverse transcription-polymerase chain reaction, and ribonucleic acid-sequencing), (5) function (conventional/ghost flow cytometry), (6) secretary protein (enzyme-linked immunosorbent assay), (7) drug response (conventional/ghost flow cytometry, microscopic observation, reverse transcription-polymerase chain reaction, and ribonucleic acid-sequencing), (8) gene expression (reverse transcription-polymerase chain reaction, and ribonucleic acid sequencing), (9) gene function (conventional/ghost flow cytometry, reverse transcription-polymerase chain reaction, and ribonucleic acid-sequencing) - - . | — |
Countries
Japan
Contacts
Public ContactRyohei Kobayashi
CPCC Company Limited Clinical Planning Department
Outcome results
None listed